Safety and efficacy of mirabegron add-on treatment to solifenacin in incontinent OAB subjects with an inadequate response to initial 4-week solifenacin monotherapy

Drake M1, Adil Esen A2, Athanasiou S3, Herholdt C4, Kaper M5, Saleem T4, Huang M4, Siddiqui E4, MacDiarmid S6

Research Type

Clinical

Abstract Category

Overactive Bladder

Abstract 490
Pharmacotherapy for Overactive Bladder
Scientific Podium Short Oral Session 34
Friday 9th October 2015
09:22 - 09:30
515ABC
Detrusor Overactivity Incontinence Overactive Bladder
1. Bristol Urological Institute, Bristol, UK, 2. Dokuz Eylül University, Izmir, Turkey, 3. University of Athens,"Alexandra" Hospital, Athens, Greece, 4. Astellas Pharma Europe Ltd, Chertsey, Surrey, UK, 5. Astellas Pharma Global Development, Leiden, Netherlands, 6. Alliance Urology Specialists, Greensboro, NC, USA
Presenter
S

Scott MacDiarmid

Links

Abstract